Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGFBR2 | P37173 | 2/20 | 0.52 |
| ▸ | RET | P07949 | 2/20 | 0.49 |
| ▸ | PIM1 | P11309 | 13/20 | 0.46 |
| ▸ | PIM2 | Q9P1W9 | 7/20 | 0.45 |
| ▸ | FYN | P06241 | 3/20 | 0.44 |
| ▸ | ACVR2A | P27037 | 1/20 | 0.44 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.44 |
| ▸ | FLT3 | P36888 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL102962 | 0.88 | FYN (0.56) | TGFBR2RETPIM1PIM2FYN | |
| SCHEMBL103006 | 0.88 | FYN (0.52) | TGFBR2RETPIM1PIM2FYN | |
| SCHEMBL102244 | 0.88 | RET (0.47) | TGFBR2RETPIM1PIM2FYN | |
| SCHEMBL102521 | 0.87 | NTRK1 (0.50) | TGFBR2PIM1PIM2FYNFLT3 | |
| SCHEMBL103007 | 0.87 | PIM1 (0.61) | TGFBR2PIM1PIM2FYNFLT3 | |
| SCHEMBL102517 | 0.85 | PIM1 (0.51) | TGFBR2RETPIM1PIM2FYN | |
| SCHEMBL103291 | 0.84 | PIM1 (0.63) | TGFBR2PIM1PIM2FLT3 | |
| SCHEMBL103014 | 0.84 | FYN (0.57) | TGFBR2RETPIM1PIM2FYN | |
| SCHEMBL102524 | 0.82 | PIM1 (0.65) | TGFBR2PIM1PIM2FYNFLT3 | |
| SCHEMBL102241 | 0.81 | FYN (0.55) | RETPIM1PIM2FYN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2086979-B1 | IMIDAZO[1,2-B]PYRIDAZINE AND PYRAZOLO[1,5-A]PYRIMIDINE DERIVATIVES AND THEIR USE AS PROTEIN KINASE INHIBITORS | TOLERO PHARMACEUTICALS INC (US) | 2015-06-03 | — | — | EP | disclosed |